Interim report
Page 1
Email – investorservices@torrentpharma.com 30th July, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5 th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) We would like to inform that the Board has at its meeting held today approved, inter alia, the Unaudited Standalone and Consolidated Financial Results along with limited review report of the Company for the quarter ended 30 th June, 2026. The said financial results are enclosed herewith as an Annexure A. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter ended 30th June, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B. We would further like to inform that Ameera Shah (DIN: 00208095) will be completing her term as an Independent Director of the Company on 01st August, 2026. The Board meeting commenced at 02:00 pm and concluded at 04:40 pm. The above is for your information and record. TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN L24230GJ1972PLC002126 Regd. Office, Avirat. Thalte j Shilaj Road, Ahmedabad - 380059 Phone, +9179 26599000, Fax, +9179 26582100, www.to rrentpharma.com
Page 2
Email – investorservices@torrentpharma.com Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A/a TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN L24230GJ1972PLC002126 Regd. Office Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone: +91 79 26599000, Fax: +91 79 26582100, www.to rrentpharma .com
Page 3
Annexure A BS R & Co. LLP 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Chartered Accountants Western Express Highway Goregaon (East), Mumbai -400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited standalone financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended To the Board of Directors of Torrent Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement") (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL). pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statem'ent in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to Note 4 to the accompanying standalone financial results, which describes the Scheme of Amalgamation (Scheme) of JBCPL with the Company, approved by the Honourable National Company Law Tribunal ("NCL T") vide its Order dated 6 July 2026 and a certified copy has been filed by the Company with the Registrar of Companies, Ahmedabad on 8 July 2026. In accordance with the scheme approved by NCL T, the amalgamation has been accounted for in the quarter ended 30 June 2026 with effect from the appointed date of 21 January 2026, and accordingly, the comparative financial information for the quarter and year ended 31 March 2026 has been restated. /j? _9.ur conclusion is not modified in respect of this matter. ~ BS R & Co. {a partnership firm wilh Registra!ion No. BA61223) converted Into BS R & Co. LLP (a Limited liability Partnership \..,.;th LLP Registration No. AAB-6181) with effect from October 14, 2013 Registered Office· 14th Floor, Central B Wing and North C \/\ling, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai-400063 Page 1 of 2
Page 4
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited 6. The corresponding amounts for the quarter and year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 4), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of JBCPL, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 7. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2026 as reported in these financial results are the balancing figures between audited figures in respect of full previous financial year as adjusted to give effect to the Scheme of Amalgamation of JBCPL with the Company which has been approved by the Honourable National Company Law Tribunal vide its order dated 6 July 2026 with the appointed date of 21 January 2026, and the audited year to date figures up to the third quarter of the previous financial year. Ahmedabad 30 July 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No :101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:26048648MGVKOE5690 Page 2 of 2
Page 5
TORREN1 PHARMA TORRENT PHARMACEUTICALS LIMITED Registered Office: "Avirat", Thaltej Shilaj Road, Ahmedabad-380059 , Gujarat, India, Ph.: + 91 79 26599000 Fax:+ 917926582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharm a.com; Email: investorservices@torrentpharma.com {Rs. in crores) Statement of Standalone Financial Results for the Quarter ended June 30, 2026 Quarter ended Year ended 30-Jun-2026 31-Mar-2026 30-Jun-2025 31-Mar-2026 Particulars Unaudited Audited, Restated Audited Audited, (Refer note 3 & 4) Restated (Refer note 4) 1 Revenue from operations (a) Revenue from contracts with customers 4073 3378 2567 11199 (b) Other operating income 85 67 49 223 Total revenue from operations 4158 3445 2616 11422 2 Other income (Refer Note 7) (21) (30) (5) (70) 3 Total income (1 + 2) 4137 3415 2611 11352 4 Expenses (a) Cost of mate rials consumed 609 561 394 1748 (b) Purchases of stock-in-trade 277 275 173 832 (c) Changes in inventories of finished goods, work -in-progress 52 (44) 17 (47) and stock-in-trade (d) Employee benefits expense 677 598 453 1990 (e) Finance costs 293 226 45 342 (f) Depreciation and amortisation expense 575 490 187 1057 (g) Other expenses 970 827 600 2620 Total expenses 3453 2933 1869 8542 5 Profit before exceptional items and tax {3 - 4) 684 482 742 2810 6 Exceptional items (Refer Note 5) 21 66 - 89 7 Profit before tax (5 - 6) 663 416 742 2721 8 Tax expense (a) Current tax 266 119 198 767 (b) Deferred tax (95) (12) (7) (80) Total tax expense 171 107 191 687 9 Net profit for the period (7 - 8) 492 309 551 2034 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to (17) 18 (9) (3) profit or loss (ii) Income tax relating to items that will not be 4 (4) 2 1 reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit 107 (97) (27) (191) or loss (ii) Income tax relating to items that will be reclassified (27) 25 7 48 subsequently to profit or loss Total other comprehensive income 67 (58} (27) (145) 11 Total comprehensive Income (9 + 10) 559 251 524 1889 12 Paid-up equity share capital (Face value of Rs. 5 each) 169.23 169.23 169.23 169.23 13 Other equity excluding revaluation reserves 17407 14 Earnings per share (Face value of Rs. 5 each) (not annualised) : Basic (in Rs.) 12.94 7.74 16.28 58.70 Diluted (in Rs.) 12.94 7.74 16.28 58.70 See accompanying notes to the standalone financial results LIAAC.~ ~~ ~(i~ ~ TORRENI' iO PMAIIMA ,.it' • ,.t,t-'O
Page 6
TORRENT'" PHARM A Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on July 30, 2026. The statutory auditors have carried out limited review of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The Company operates in a single segment i.e. Generic Formulation Business. 3 Figures for the quarter ended March 31, 2026 represents the difference between the audited figures in respect to the full financial year {as restated as per Note 4 below) and the published figures of nine months ended December 31, 2025, which were subjected to audit. 4 On January 21, 2026, the Company acquired controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited {JB Pharma). The Scheme of Amalgamation of JB Pharma with the Company was approved by the Hon'ble National Company Law Tribunal {NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrars of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Company and dissolved without being wound up. On July 20, 2026, the Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 fully paid up equity shares having face value of Rs. 5 each of the Company for every 100 fully paid up equity shares having face value of Rs. 1 each of JB Pharma. The management has determined the amalgamation to be a subsequent adjusting event and impact of amalgamation has been accounted using the pooling of interest method in accordance with Appendix C to Ind AS 103, Business Combinations, with effect from the appointed date, January 21, 2026, as specified in the approved Scheme. Accordingly, the comparative financial information for the year and quarter ended March 31, 2026, has been restated after recognizing the effect of amalgamation as above. The amount of Revenue from operations and profit before tax published in the previous period before recognizing the effect of amalgamation are shown below - ( Rs. In crores) Particulars Quarter ended Yearended 31-Mar-2026 31-Mar-2026 Total revenue from operations 2735 10712 Profit Before Tax 592 2897 The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority. S Exceptional items (i)lncludes Rs. 2 crores for the quarter ended June 30, 2026, Rs. 47 crores and Rs. 70 crores for quarter and year ended March 31, 2026 respectively, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 4 above. (ii)lncludes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment. {iii)lncludes severance compensation of Rs. 19 crores for the quarter and year ended .March 31, 2026, incurred on account of restructuring of JB Pharma's distribution network. 6 The listed non-convertible debentures of the company aggregating Rs. 10990 crores as at June 30, 2026 (as at March 31, 2026 : Rs.10990 Crores) are secured by first ranking exclusive charge by way of hypothecation over the designated account assets and the specified trademarks of the company including its future line extensions. The security cover thereof exceeds 110% of the principal amount and interest accrued on the said debentures . The listed non-convertible debentures of the company aggregating Rs. 143 crores as at March 31, 2025 has been fully repaid during the year ended March 31, 2026.
Page 7
TORRENT'" PHARMA 7 Other income mainly includes interest income, dividend income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 8 Refer Annexure I for disclosure required pursuant to Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Place : Ahmedabad, Gujarat Date : July 30, 2026 For TORRENT PHARMACEUTICALS LIMITED ,../ ,. - ¾ / / A NMEHTA Managing Director DIN : 08174906
Page 8
TORRENT'" PHARMA ANNEXURE I: (Rs. in crores except as stated otherw ise) Additional Disclosure as per regulation 52(4) and 54(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Regulation No. Paid up debt capital Net worth 52(4)(f) Debenture redemption reserve 52(4)(e) Debt equity ratio (in times) 52(4)(a) Debt service coverage ratio (in times) 52(4)(b) Interest service coverage ratio (in times) 52(4)(c) Current ratio (in times) 52(4)(i) Long term debt to working capital (in times) 52(4)(j) Bad debts to Account receivables ratio (in times) 52(4)(k) Current liability ratio (in times) 52(4)(1) Total debts to total assets (in times) 52(4)(m) Debtors turnover (in times) (Annualised) 52(4)(n) Inventory turnover (in times) (Annualised) 52(4)(0) Operating margin (in %) 52(4)(p) Net profit margin (in %) 52(4)(q) Security cover ratio (in times) 54(3) Ratios have been computed as follows :- (a) Debt equity ratio : Total debt/ Net worth Total debt: Non-current borrowings+ current borrowings Net worth : Equity share capital+ Other equity 30-Jun-2026 11390 17754 - 0.78 3.88 4.40 1.29 5.55 0.01 0.26 0.33 4.67 7.52 37.2% 11.8% 1.44 Quarter ended Year ended 31-Mar-2026 30-Jun-2025 31-Mar-2026 (Restated) (Restated) 11390 643 11390 17576 8117 17576 - 36 - 0.81 0.27 0.81 3.85 5.55 3.27 4.77 17.21 10.09 1.22 1.71 1.22 7.29 0.60 7.29 0.01 0.00 0.01 0.26 0.56 0.26 0.34 0.17 0.34 4.74 4.52 4.06 7.26 6.63 6.00 34.6% 37.2% 36.8% 9.0% 21.1% 17.8% 1.47 9.41 1.47 (b) Debt service coverage ratio : (Profit after tax+ Deferred tax+ Depreciation and amortisation+ Interest on debt and lease+ Exceptional items)/ (Interest on debt and lease + Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio: (Profit after tax+ Deferred tax+ Depreciation and amortisation+ Interest on debt and lease+ Exceptional items)/ Interest on debt and lease (d) Current Ratio : Total current assets/ Total current liabilities (e) L<:Jng term debt to working capital : Non-current borrowings (incl. current maturities of long-term borrowings)/ Net working capital Net Working capital : Total current assets - Current liabilities Current liabilities: Total current liabilities - current maturities of long-term borrowings (f) Bad debts to Account receivables ratio : Allowances for expected credit loss/ Gross trade receivables (g) Current liability ratio : Total current liabilities/ Total liabilities (h) Total debts to total assets : Total borrow ing/ Total assets (i) (j) Total borrowing: Non-current borrowings+ current borrowings Debtors turnover : Net sales/ Average trade receivables Inventory turnover: Net sales/ Average Inventories (k) Operating margin%: Revenue from operations - (cost of goods sold+ employee benefits+ other expenses)+ (other income - interest income - dividend income) / Revenue from operations (I) Net profit margin%: Profit after tax/ Revenue from operations (m) Security cover ratio: Total assets available for secured debt securities (secured by either pari-passu or exclusive charge on assets including assets given on first pari-passu basis to term loan lenders)/ Total borrowing through issue of secured Debt securities and other borrowings (secured by first pari-passu charge on aforementioned assets) including interest accrued.
Page 9
8 SR & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, India Telephone +91 (22) 6257 1000 Fax +91 (22) 6257 1010 Limited Review Report on unaudited consolidated financial_ results of Torrent Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended To the Board of Directors of Torrent Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021 /613 dated 10 August 2021, as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Petformed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly , we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement. 5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. 8 SR & Co. (a partner::.hip firm with Registration No. BA61223) converted into BS R & Co. LLP (a Limited Liabili1~• Partnership with LLP Regis1ration No. AAB-81 81) with effect from October 14, 2013 Registered Office: 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Cenler, Western Express High-.wy, Goregaon (East}, Mumbai - 400063 Page 1 of4
Page 10
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited 6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Ahmedabad 30 July 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No.: 101248W/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:26048648WWLMKT5706 Page 2 of 4
Page 11
BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited Annexure I List of entities included in unaudited consolidated financial results. Sr. No Name of component Relationship 1 Torrent Pharmaceuticals Limited Parent 2 Zao Torrent Pharma Wholly Owned Subsidiary 3 Torrent Do Brasil Ltda Wholly Owned Subsidiary 4 Torrent Pharma Gmbh Wholly Owned Subsidiary 5 Heumann Pharma Gmbh & Co. Generica KG Wholly Owned Step down Subsidiary 6 Heunet Pharma Gmbh Wholly Owned Step down Subsidiary 7 Torrent Pharma Inc. Wholly Owned Subsidiary 8 Torrent Pharma Philippines Inc. Wholly Owned Subsidiary 9 Laboratories Torrent, S.A. de C.V. Wholly Owned Subsidiary 10 Torrent Australasia Pty Ltd Wholly Owned Subsidiary 11 Torrent Pharma (Thailand) Co., Ltd. Wholly Owned Subsidiary 12 Torrent Pharma (UK) Ltd. Wholly Owned Subsidiary 13 Laboratories Torrent (Malaysia) SDN.BHD. Wholly Owned Subsidiary 14 TPL (Malta) Limited Wholly Owned Subsidiary 15 Torrent Pharma (Malta) Limited Wholly Owned Step down Subsidiary 16 Curatio Inc., Philippines (voluntary dissolved Wholly Owned Subsidiary with effect from 10 July 2026) 17 Torrent International Lanka (Pvt) Ltd (Formerly Wholly Owned Subsidiary known as Curatio International Lanka (Pvt) Ltd), Sri Lanka C ~ ! c~ Farmaceutica Torrent Colombia SAS Wholly Owned Subsidiary lb 'I"~ ~ ;., I . ~ ~ ~ r;:- Page 3 or 4 .,., ~,._'I> 9r:/Acco\) , -
Page 12
BS R & Co. LLP 19 Torrent Pharmaceuticals Chile SpA 20 000 Unique Pharmaceutical Laboratories 21 Unique Pharmaceutical Laboratories FZE 22 Biotech Laboratories JBCPL Philippines Inc. Limited Review Report (Continued) Torrent Pharmaceuticals Limited Wholly Owned Subsidiary Wholly Owned Subsidiary Wholly Owned Subsidiary Wholly Owned Step down Subsidiary Wholly Owned Step down Subsidiary Page 4 of4
Page 13
TORREN1 TORRENT PHARMACEUTICALS LIMITED PHARMA Registered Office: "Avirat", Thaltej Shilaj Road, Ahmedabad - 380059, Gujarat, India, Ph.:+ 91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com Statement of Consolidated Financial Results for the Quarter ended June 30, 2026 Particulars 1 Revenue from operations (a) Revenue from contracts with customers (b) Other operating income Total revenue from operations 2 Other income (Refer Note 8) 3 Total income (1+2) 4 Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortisation expense (g) Other expenses Total expenses 5 Profit before exceptional items and tax (3 - 4) 6 Exceptional items (Refer Note 7) 7 Profit before tax (5 - 6) 8 Tax expense (a) Current tax (b) Deferred tax Total tax expense 9 Net profit for the period (7 - 8) Attributable to : (a) Owners of the company (b) Non-controlling interests 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to profit or loss* (ii) Income tax relating to items that will not be reclassified subsequently to profit or loss* (B) (i) Items that will be reclassified subsequently to profit or loss (ii) Income tax relating to items that will be reclassified subsequently to profit or loss Total other comprehensive income Attributable to : (a) Owners of the company (b) Non-controlling interests 11 Total comprehensive Income (9 + 10) Attributable to : (a) Owners of the company (b) Non-controlling interests 12 Paid-up equity share capital (Face value of Rs. 5 each) 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised) : Basic (in Rs.) Diluted (in Rs.) See accompanying notes to the consolidated financial results *Represents value less than Rs. 0.50 crore . 30-Jun-2026 Unaudited (Refer Note 6) 4835 86 4921 (12) 4909 609 531 23 893 305 593 1201 4155 754 21 733 254 (87) 167 566 566 (17) 4 119 (27) 79 79 645 645 169.23 14.87 14.87 Quarter ended 31-Mar-2026 Audited (Refer Note 4 & 5) 4128 69 4197 (17) 4180 566 477 (28) 788 236 508 1,038 3585 595 66 529 166 (1) 165 364 389 (25) 21 (4) (127) 24 (86) (87) 1 278 302 (24) 169.23 11.51 11.51 30-Jun-2025 Unaudited (Refer Note 6) 3128 so 3178 (37) 3141 396 338 40 605 56 201 767 2403 738 738 201 (11) 190 548 548 (9) 2 (2) 7 (2) (2) 546 546 169.23 16.19 16.19 (Rs. in crores) Year ended 31-Mar-2026 Audited (Refer Note 5) 13753 227 13980 (94) 13886 1758 1619 11 2671 385 1119 3362 10925 2961 89 2872 844 (110) 734 2138 2163 (25) 0 0 (228) 48 (180) (181) 1 1958 1982 (24) 169.23 8220 63.92 63.92
Page 14
TORRENT" PHARMA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on July 30, 2026. The statutory auditors have carried out limited review of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The consolidated financial results include the financial results of Parent Company and its twenty-two subsidiaries. 3 The Group operates in a single segment i.e. Generic Formulation Business. 4 Figures for the quarter ended March 31, 2026 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2025, which were subjected to limited review. 5 Consequent to the acquisition of the controlling stake of 48.80% in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), the Parent Company obtained control over JB Pharma in accordance with Ind AS 110 - Consolidated Financial Statements with effect from January 21, 2026. The results for the year and quarter ended March 31, 2026, includes the financial results of JB Pharma and its subsidiaries w.e.f. January 21, 2026. 6 The Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with the Parent Company was approved by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026. Upon filing the Scheme with Registrar of Companies (ROC), the Scheme became effective on July 8, 2026, with an appointed date of January 21, 2026. Consequently, JB Pharma has been amalgamated with the Parent Company and dissolved without being wound up. On July 20, 2026, the Parent Company allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JB Pharma as on the record date, July 17, 2026, in the share exchange ratio of 51 equity shares having face value of Rs. 5 each of the Parent Company for every 100 equity shares having face value of Rs. 1 each of JB Pharma. Upon Scheme becoming effective, the non-controlling interest relating to JB Pharma has been derecognised in the consolidated financial results. The amalgamation has no material impact on the consolidated financial results. The financial results do not include the effect of the stamp duty payable in respect of the Scheme of Amalgamation, pending adjudication by the appropriate authority. 7 Exceptional items (i) Includes Rs. 2 crores for the quarter ended June 30, 2026, Rs. 47 crores and Rs. 70 crores for quarter and year ended March 31, 2026 respectively, pertaining to regulatory and statutory fees, along with other related costs associated with JB Pharma's acquisition and merger as mentioned in Note 5 and 6 above. (ii) Includes inventory write-off of Rs. 19 crores for the quarter ended June 30, 2026 consequent to fire incident at one of the erstwhile JB Pharma warehouses. No effect has been given to the related insurance claim, which is under assessment. (iii) Includes severance compensation of Rs. 19 crores for the quarter and year ended March 31, 2026, incurred on account of restructuring of JB Pharma's distribution network.
Page 15
TORRENT" PHARMA 8 Other income mainly includes interest income, net gain on sale of investments, net foreign exchange gain/(loss) and net gain/(loss) on disposal of property, plant & equipment and other intangible assets. 9 Refer Annexure I for disclosure required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Place : Ahmedabad, Gujarat Date : July 30, 2026 For TORRENT PHARMACEUTICALS LIMITED Managing Director DIN: 08174906
Page 16
TORRENT" PHA RMA ANNEXURE I: (Rs. In crores except as stated otherwise) Additional Disclosure as per regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Regulation Quarter ended Year ended No. 30-Jun-2026 31-Mar-2026 30-Jun-2025 31-Mar-2026 Paid up debt capital Net worth Debenture redemption reserve Debt equity ratio (in times) Debt service coverage ratio (in times) Interest service coverage ratio (in times) Current ratio (in times) Long term debt to working capital (in times) Bad debts to Account receivables ratio (in times) Current liability ratio (in times) Total debts to total assets (in times) Debtors turnover (in times) (Annualised) Inventory turnover (in times) (Annualised) Operating margin (in %) Net profit margin (in %} Ratios have been computed as follows :- (a) Debt equity ratio : Total debt/ Net worth Total debt: Non-current borrowings+ current borrowings Net worth : Equity share capital+ Other equity 11390 52(4)(f) 17848 52(4)(e) - 52(4)(a) 0.82 52(4)(b) 3.98 52(4)(c) 4.60 52(4)(i) 1.20 52(4)0) 6.37 52(4)(k) 0.02 52(4)(1) 0.31 52(4)(m) 0.33 52(4)(n) 6.09 52(4)(0) 6.14 52(4)(p) 33.2% 52(4)(q) 11.5% 11390 643 11390 8389 8137 8389 - 36 - 1.76 0.33 1.76 4.09 5.10 3.26 4.97 14.20 9.41 1.13 1.35 1.13 9.26 0.83 9.26 0.02 0.01 0.02 0.31 0.62 0.31 0.33 0.18 0.33 6.60 6.73 5.62 5.87 4.97 4.84 31.5% 31.1% 31.7% 8.7% 17.2% 15.3% (b) Debt service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / (Interest on debt and lease+ Principal repayments of long term debt including lease payment) (c) Interest service coverage ratio : (Profit after tax+ Deferred tax+ Depreciation and amortisation + Interest on debt and lease + Exceptional items)/ Interest on debt and lease (d) Current Ratio: Total current assets/ Total current liabilities (e) Long term debt to working capital : Non-current borrowings (including current maturities of long-term borrowings)/ Net working capital Net Working capital : Total current assets - Current liabilities Current liabilities: Total current liabilities - current maturities of long-term borrowings (fl Bad debts to Account receivables ratio : Allowances for expected credit loss/ Gross trade receivables (g) Current liability ratio : Total current liabilities/ Total liabilities (h) Total debts to total assets: Total borrowing/ Total assets Total borrowing: Non-current borrow ings+ current borrowings (i) Debtors turnover: Net sales/ Average trade receivables U) Inventory turnover : Net sales/ Average Inventories (k) Operating margin%: Revenue from operations - (cost of goods sold+ employee benefits+ other expenses)+ (other income - interest income - dividend income)/ Revenue from operations (I) Net profit margin% : Profit after tax/ Revenue from operations
Page 17
Torrent Pharma announces Q1 FY27 results India business delivers record high organic growth; JB Business revenues up 10% Ah medabad, 30 th July 2026: Torrent Pharmaceuticals Limited (“Company”) today announced its financial results for the first quarter of FY27. Key Highlights for Q1 FY27: Revenue at Rs. 4,921 crores, up by 55% YoY Op. EBITDA* at Rs.1,664 crores, up by 61% YoY Op. EBITDA* margin at 33.8%; Gross Margin at 76.4% Net Profit after tax at Rs. 566 crores *Before exceptional items Consolidated Financial Summary: Results Q1 FY27 Q1 FY26 YoY % Rs cr % Rs cr % Revenues 4,921 3,178 55% Gross profit 3,758 76.4% 2,404 75.6% 56% Op. EBITDA* 1,664 33.8% 1,032 32.5% 61% Exceptional items 21 0.4% - - - PAT 566 11.5% 548 17.2% 3% R&D spend 172 4% 157 5% 10% Annexure B TORRENI MEDIA RELEASE PHARMA In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road. Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 18
Base Business Base business revenues at Rs. 3,720 crores were up 17% Op. EBITDA* at Rs. 1,240 crores grew by 20%, with margins of 33.3% India: India revenues at Rs. 2,157 crores were up 19% vs IPM growth of 12%, as per the AIOCD PharmaTrac dataset Torrent is now ranked 1 st in the IPM cardiac market, and continues strong outperformance in the segment Following a strong start, Gx Semaglutide recorded Q1 FY27 market share of 36% (oral and injectable combined), as per AIOCD PharmaTrac Data Brazil: Brazil revenues at Rs. 277 crores were up 27%. Constant currency revenues at R$ 147 million were up by 3%. As per IQVIA, Torrent grew 21% vs market growth of 5%, aided by the performance of top brands and recent launches. Torrent has 58 products under ANVISA review During the quarter, the Company undertook a one-time channel inventory reduction in response to channel requests for extended credit periods amid rising interest costs. Secondary sales continue to reflect underlying demand momentum as reflected in IQVIA data. United States: US revenues at Rs. 418 crores were up 36%. Constant currency revenues at US$ 44 million were up by 23% Performance is driven by new launches achieving targeted market share and certain one-time opportunities. Germany: Germany revenues at Rs. 318 crores were up 3%. Constant currency revenues at EUR 29 million were down by 9% Growth continued to be impacted by supply disruption at a third-party supplier and lower tender offtake during the quarter TORRENI MEDIA RELEASE PHARMA In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road. Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 19
JB Business Results Q1 FY27 Q1 FY26 YoY % Rs cr % Rs cr % Revenues 1,201 1,094 10% Gross profit 859 71.5% 747 68.3% 15% Op. EBITDA* 424 35.3% 315 28.8% 34% Exceptional items 19 1.6% - - - * Before exceptional items and one offs Key Performance Metrics: India Rx business (ex of trade generics + contrast media) at Rs. 657 cr grew by 13% International business (US + Emerging Markets + CDMO) revenues at Rs. 468 crores were up 12% o CDMO business revenues at Rs. 145 crores were up 27% Consolidated Revenue Summary Region Q1 FY27 (Rs. crore) Q1 Growth (%) Base JB Total Base Reported Business Business Business India 2,157 733 2,890 19% 60% International 1,451 468 1,919 19% 57% Others 112 - 112 -24% -24% Total 3,720 1,201 4,921 17% 55% TORRENI MEDIA RELEASE PHARMA In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396 TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road. Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com
Page 20
About Torrent Pharmaceuticals: Torrent Pharma is the flagship Company of the Torrent Group, with group revenues of approximately Rs 50,000 crores. It is ranked 5 th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Derma. It is a specialty-focused company with ~75% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent Pharma has 16 manufacturing facilities, of which 8 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 900+ scientists. TORRENI MEDIA RELEASE PHARMA In case of any enquiry / clarificatio n, please contact Mr. Jayesh Desai on +9 1 9824501396 TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000 , Fax, +91 79 26582100, www.torrentpharma.com